Hepatocellular carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages 3994-4005

  Thomas, Melanie B ^a   Jaffe, Deborah ^a   Choti, Michael M ^a   Belghiti, Jacques ^a   Curley, Steven ^a   Fong, Yuman ^a   Gores, Gregory ^a   Kerlan, Robert ^a   Merle, Phillipe ^a   O'Neil, Bert ^a   Poon, Ronnie ^a   Schwartz, Lawrence ^a   Tepper, Joel ^a   Yao, Francis ^a   Haller, Daniel ^a   Mooney, Margaret ^a   Venook, Alan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BRIVANIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GELFOAM; IODINATED POPPYSEED OIL; LINIFANIB; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; SORAFENIB; VASCULOTROPIN; YTTRIUM 90;

CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; EVIDENCE BASED PRACTICE; HEALTH CARE NEED; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; UNITED STATES; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; HEALTH CARE PLANNING; LIVER TUMOR; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HEALTH PLANNING GUIDELINES; HUMANS; LIVER NEOPLASMS; TREATMENT OUTCOME;

EID: 77957603190     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.7805     Document Type: Review

References (148)

1. Jemal A, Ward E, Hao Y, et al: Trends in the leading causes of death in the United States, 1970-2002. JAMA 294:1255-1259, 2005
2. Bosch FX, Ribes J, Díaz M, et al: Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127:S5-S16, 2004 (Pubitemid 39423365)
3. Edwards BK, Ward E, Kohler BA, et al: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544-573, 2010
4. Kim WR: Epidemiology of hepatitis B in the United States. Hepatology 49:S28-S34, 2009
5. Bialecki ES, Di Bisceglie AM: Diagnosis of hepatocellular carcinoma. HPB (Oxford) 7:26-34, 2005 (Pubitemid 40425754)
6. Clark HP, Carson WF, Kavanagh PV, et al: Staging and current treatment of hepatocellular carcinoma. Radiographics 25:S3-S23, 2005 (suppl 1) (Pubitemid 41686059)
7. Palavecino M, Chun YS, Madoff DC, et al: Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 145:399-405, 2009
8. Colombo M: Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis 19:263-269, 1999
9. Chu CM, Liaw YF: Hepatitis B virus-related cirrhosis: Natural history and treatment. Semin Liver Dis 26:142-152, 2006
10. Perz JF, Armstrong GL, Farrington LA, et al: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529-538, 2006 (Pubitemid 44307383)
11. Saab S, Yeganeh M, Nguyen K, et al: Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 15:1525-1534, 2009
12. Tong MJ, Hsien C, Song JJ, et al: Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Dig Dis Sci 54:1337-1346, 2009
13. Schütte K, Bornschein J, Malfertheiner P: Hepatocellular carcinoma: Epidemiological trends and risk factors. Dig Dis 27:80-92, 2009
14. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750, 1999 (Pubitemid 29114292)
15. Chiaramonte M, Stroffolini T, Vian A, et al: Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 85:2132-2137, 1999 (Pubitemid 29215551)
16. Marrero JA, Fontana RJ, Su GL, et al: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36:1349-1354, 2002 (Pubitemid 35403524)
17. Chávez-Tapia NC, Méndez-Sánchez N, Uribe M: Role of nonalcoholic fatty liver disease in hepatocellular carcinoma. Ann Hepatol 8:S34-S39, 2009 (suppl 1)
18. Siegel AB, Zhu AX: Metabolic syndrome and hepatocellular carcinoma: Two growing epidemics with a potential link. Cancer 115:5651-5661, 2009
19. Page JM, Harrison SA: NASH and HCC. Clin Liver Dis 13:631-647, 2009
20. Jaskiewicz K, Banach L, Lancaster E: Hepatic siderosis, fibrosis and cirrhosis: The association with hepatocellular carcinoma in high-risk population. Anticancer Res 17:3897-3899, 1997 (Pubitemid 28014958)
21. Budhu A, Forgues M, Ye QH, et al: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10:99-111, 2006 (Pubitemid 44202603)
22. Honda H, Tajima T, Kajiyama K, et al: Vascular changes in hepatocellular carcinoma: Correlation of radiologic and pathologic findings. AJR Am J Roentgenol 173:1213-1217, 1999 (Pubitemid 29493992)
23. Roncalli M, Borzio M, Di Tommaso L: Hepatocellular dysplastic nodules. Ann Ital Chir 79:81-89, 2008
24. Shinmura R, Matsui O, Kadoya M, et al: Detection of hypervascular malignant foci in borderline lesions of hepatocellular carcinoma: Comparison of dynamic multi-detector row CT, dynamic MR imaging and superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 18:1918-1924, 2008
25. Kitamura T, Ichikawa T, Erturk SM, et al: Detection of hypervascular hepatocellular carcinoma with multidetector-row CT: Single arterialphase imaging with computer-assisted automatic bolus-tracking technique compared with double arterial-phase imaging. J Comput Assist Tomogr 32:724-729, 2008
26. Kim MJ, Choi JY, Chung YE, et al: Magnetic resonance imaging of hepatocellular carcinoma using contrast media. Oncology 75:72-82, 2008 (suppl 1)
27. Therasse P, Eisenhauer EA, Verweij J: RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 42:1031-1039, 2006
28. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
29. Kharuzhyk S, Fabel M, von Tengg-Kobligk H, et al: Image-based evaluation of tumor response to treatment: Where is radiology today? Exp Oncol 30:181-189, 2008
30. Choi BI: Hepatocarcinogenesis in liver cirrhosis: Imaging diagnosis. J Korean Med Sci 13:103-116, 1998
31. Menu Y: [Evaluation of tumour response to treatment with targeted therapies: Standard or targeted criteria?]. Bull Cancer 94:F231-F239, 2007
32. Lu W, Dong J, Huang Z, et al: Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroenterol Hepatol 23:1874-1878, 2008
33. Cho CS, Gonen M, Shia J, et al: A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg 206:281-291, 2008
34. Georgiades CS, Liapi E, Frangakis C, et al: Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol 17:1619-1624, 2006 (Pubitemid 44581175)
35. Collette S, Bonnetain F, Paoletti X, et al: Prognosis of advanced hepatocellular carcinoma: Comparison of three staging systems in two French clinical trials. Ann Oncol 19:1117-1126, 2008 (Pubitemid 351796337)
36. Edge SB, Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC Cancer Staging Manual and the future of TNM. Ann Surg Oncol 17:1471-1474, 2010
37. Vauthey JN, Lauwers GY, Esnaola NF, et al: Simplified staging for hepatocellular carcinoma. J Clin Oncol 20:1527-1536, 2002 (Pubitemid 34260532)
38. Gunderson LL, Jessup JM, Sargent DJ, et al: Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol 28:256-263, 2010
39. Llovet JM, Brú C, Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19:329-338, 1999
40. Lucey MR, Brown KA, Everson GT, et al: Minimal criteria for placement of adults on the liver transplant waiting list: A report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 3:628-637, 1997 (Pubitemid 27498478)
41. Pugh RC: Proceedings: The pathology of cancer of the bladder. Cancer 32:1267-1274, 1973
42. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma - The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 31:840-845, 2000
43. Leung TW, Tang AM, Zee B, et al: Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients. Cancer 94:1760-1769, 2002 (Pubitemid 34241115)
44. Cammà C, Di Marco V, Cabibbo G, et al: Survival of patients with hepatocellular carcinoma in cirrhosis: A comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 28:62-75, 2008 (Pubitemid 351782806)
45. Makuuchi M, Belghiti J, Belli G, et al: IHPBA concordant classification of primary liver cancer: Working group report. J Hepatobiliary Pancreat Surg 10:26-30, 2003 (Pubitemid 36850300)
46. Nanashima A, Sumida Y, Morino S, et al: The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. Eur J Surg Oncol 30:765-770, 2004 (Pubitemid 39107067)
47. Ikai I, Takayasu K, Omata M, et al: A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol 41:884-892, 2006 (Pubitemid 44594230)
48. Hayashi PH, Trotter JF, Forman L, et al: Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl 10:42-48, 2004 (Pubitemid 38885891)
49. Yao FY, Ferrell L, Bass NM, et al: Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 8:765-774, 2002 (Pubitemid 35012284)
50. Okuda K, Ohtsuki T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment: Study of 850 patients. Cancer 56:918-928, 1985 (Pubitemid 15228292)
51. Kulik LM: Can therapy of hepatitis C affect the development of hepatocellular carcinoma? J Natl Compr Canc Netw 4:751-757, 2006
52. Tokita H, Fukui H, Tanaka A, et al: Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 20:752-758, 2005 (Pubitemid 40733371)
53. Giannini EG, Bodini G, Corbo M, et al: Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 31:493-501, 2010
54. Chang MH, You SL, Chen CJ, et al: Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: A 20-year follow-up study. J Natl Cancer Inst 101:1348-1355, 2009
55. Beasley RP: Rocks along the road to the control of HBV and HCC. Ann Epidemiol 19:231-234, 2009
56. Omata M, Yoshida H: Prevention and treatment of hepatocellular carcinoma. Liver Transpl 10:S111-S114, 2004 (Pubitemid 38240110)
57. Kane RC, Farrell AT, Madabushi R, et al: Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14:95-100, 2009
58. Lang L: FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 134:379, 2008
59. Garc?́a-Compean D, Jaquez-Quintana JO, Maldonado-Garza H: Hepatogenous diabetes: Current views of an ancient problem. Ann Hepatol 8:13-20, 2009
60. Zhong YD, Yang YF: Diabetes mellitus, chronic hepatitis C, and hepatocellular carcinoma. Hepatology 48:1348, 2008
61. Chuang SC, La Vecchia C, Boffetta P: Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett 286:9-14, 2009
62. Choi E Rogers E, Ahmad S, et al: Hepatobiliary cancers, in Feig BW, Berger DH, Fuhrman GM (eds): The M. D. Anderson Surgical Oncology Handbook. Philadelphia, PA, Lippincott Williams & Wilkins, 2006
63. Taura K, Ikai I, Hatano E, et al: Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: An analysis of 293 patients. Surgery 142:685-694, 2007 (Pubitemid 350018839)
64. Cunningham SC, Tsai S, Marques HP, et al: Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis. Ann Surg Oncol 16:1820-1831, 2009
65. Nuzzo G, Giuliante F, Gauzolino R, et al: Liver resections for hepatocellular carcinoma in chronic liver disease: Experience in an Italian centre. Eur J Surg Oncol 33:1014-1018, 2007 (Pubitemid 47408730)
66. Llovet JM, Fuster J, Bruix J: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 30:1434-1440, 1999
67. Shah SA, Cleary SP, Tan JC, et al: An analysis of resection vs transplantation for early hepatocellular carcinoma: Defining the optimal therapy at a single institution. Ann Surg Oncol 14:2608-2614, 2007 (Pubitemid 47389575)
68. Vauthey JN, Klimstra D, Franceschi D, et al: Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 169:28-34, 1995
69. Teh SH, Christein J, Donohue J, et al: Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 9:1207-1215, 2005 (Pubitemid 41751112)
70. Pugh S, Lewis S, Rees Smith P: Bleeding oesophageal varices in alcoholic cirrhosis: Long-term follow-up of endoscopic sclerotherapy. Q J Med 86:241-245, 1993 (Pubitemid 23136293)
71. Helling TS, Woodall CE 3rd: Referrals for surgical therapy in patients with hepatocellular carcinoma: A community experience. J Gastrointest Surg 11:76-81, 2007
72. Cucchetti A, Ercolani G, Vivarelli M, et al: Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 12:966-971, 2006 (Pubitemid 43960373)
73. Poon RT, Fan ST, Lo CM, et al: Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: Implications for a strategy of salvage transplantation. Ann Surg 235:373-382, 2002 (Pubitemid 34183888)
74. Cha C, Fong Y, Jarnagin WR, et al: Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 197:753-758, 2003 (Pubitemid 38199576)
75. Ringe B, Pichlmayr R, Wittekind C, et al: Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients. World J Surg 15:270-285, 1991
76. Bismuth H, Farges O, Castaing D, et al: Assessment of the results of liver transplantation and definition of criteria for the evaluation of transplant centers. Transplant Proc 29:456-458, 1997 (Pubitemid 27123484)
77. Mazzaferro V, Regalia E, Doci R, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693-699, 1996 (Pubitemid 26079803)
78. Yao FY, Ferrell L, Bass NM, et al: Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394-1403, 2001 (Pubitemid 32496976)
79. Yao FY, Bass NM, Nikolai B, et al: Liver transplantation for hepatocellular carcinoma: Analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 8:873-883, 2002 (Pubitemid 35154015)
80. Silva M, Moya A, Berenguer M, et al: Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl 14:1449-1460, 2008
81. Takada Y, Ito T, Ueda M, et al: Living donor liver transplantation for patients with HCC exceeding the Milan criteria: A proposal of expanded criteria. Dig Dis 25:299-302, 2007 (Pubitemid 350014956)
82. Lu X, Lee M, Tran T, et al: High level expression of apoptosis inhibitor in hepatoma cell line expressing Hepatitis B virus. Int J Med Sci 2:30-35, 2005 (Pubitemid 40935434)
83. Heckman JT, Devera MB, Marsh JW, et al: Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol 15:3169-3177, 2008
84. Pompili M, Francica G, Rapaccini GL: Bridge treatments of hepatocellular carcinoma in cirrhotic patients submitted to liver transplantation. Dig Dis Sci 53:2830-2831, 2008
85. Belghiti J, Carr BI, Greig PD, et al: Treatment before liver transplantation for HCC. Ann Surg Oncol 15:993-1000, 2008
86. Zimmerman MA, Ghobrial RM, Tong MJ, et al: Recurrence of hepatocellular carcinoma following liver transplantation: A review of preoperative and postoperative prognostic indicators. Arch Surg 143:182-188, 2008 (Pubitemid 351281631)
87. Lin SM, Lin CJ, Lin CC, et al: Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54:1151-1156, 2005
88. Hong SN, Lee SY, Choi MS, et al: Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 39:247-252, 2005
89. Livraghi T, Goldberg SN, Lazzaroni S, et al: Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection. Radiology 210:655-661, 1999 (Pubitemid 29124024)
90. Shirakami Y, Shimizu M, Adachi S, et al: (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factorvascular endothelial growth factor receptor axis. Cancer Sci 100:1957-1962, 2009
91. Malagari K, Pomoni M, Kelekis A, et al: Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:541-551, 2010
92. Bruix J, Sala M, Llovet JM: Chemoembolization for hepatocellular carcinoma. Gastroenterology 127:S179-S188, 2004 (Pubitemid 39423386)
93. Brown DB, Pilgram TK, Darcy MD, et al: Hepatic arterial chemoembolization for hepatocellular carcinoma: Comparison of survival rates with different embolic agents. J Vasc Interv Radiol 16:1661-1666, 2005 (Pubitemid 44431163)
94. Biselli M, Andreone P, Gramenzi A, et al: Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: A case-controlled study. Clin Gastroenterol Hepatol 3:918-925, 2005 (Pubitemid 41219296)
95. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171, 2002 (Pubitemid 34454013)
96. Llovet JM, Real MI, Montaña X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359:1734-1739, 2002 (Pubitemid 34607087)
97. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma: Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 332:1256-1261, 1995
98. Pelletier G, Roche A, Ink O, et al: A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11:181-184, 1990
99. Thornton RH, Covey A, Petre EN, et al: A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years. Cancer 115:5000-5006, 2009
100. Taieb J, Barbare JC, Boussaha T, et al: [Management of hepatocellular carcinoma. Where are we now? What's next?]. Bull Cancer 96:19-34, 2009
101. Simonetti RG, Liberati A, Angiolini C, et al: Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. Ann Oncol 8:117-136, 1997 (Pubitemid 27112878)
102. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
103. Abou-Alfa GK, Venook AP: The impact of new data in the treatment of advanced hepatocellular carcinoma. Curr Oncol Rep 10:199-205, 2008
104. Chaparro M, González Moreno L, Trapero-Marugán M, et al: Review article: Pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 28:1269-1277, 2008
105. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009
106. Nannini M, Pantaleo MA, Maleddu A, et al: Gene expression profiling in colorectal cancer using microarray technologies: Results and perspectives. Cancer Treat Rev 35:201-209, 2009
107. Weigelt K, Lichtinger M, Rehli M, et al: Transcriptomic profiling identifies a PU.1 regulatory network in macrophages. Biochem Biophys Res Commun 380:308-312, 2009
108. Jonas S, Al-Abadi H, Benckert C, et al: Prognostic significance of the DNA-index in liver transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg 250:1008-1013, 2009
109. Realdi G, Fattovich G, Hadziyannis S, et al: Survival and prognostic factors in 366 patients with compensated cirrhosis type B: A multicenter study - The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 21:656-666, 1994 (Pubitemid 24324044)
110. Ren N, Ye QH, Qin LX, et al: Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J Gastroenterol 12:3911-3914, 2006 (Pubitemid 44028408)
111. Wang W, Peng JX, Yang JQ, et al: Identification of gene expression profiling in hepatocellular carcinoma using cDNA microarrays. Dig Dis Sci [epub ahead of print on January 1, 2009]
112. Thorgeirsson SS, Lee JS, Grisham JW: Functional genomics of hepatocellular carcinoma. Hepatology 43:S145-S150, 2006
113. Inoue T, Kudo M, Hatanaka K, et al: Imaging of hepatocellular carcinoma: Qualitative and quantitative analysis of postvascular phase contrast-enhanced ultrasonography with sonazoid - Comparison with superparamagnetic iron oxide magnetic resonance images. Oncology 75:48-54, 2008 (suppl 1)
114. Zhu AX, Sahani DV, Duda DG, et al: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 27:3027-3035, 2009
115. Woodall CE, Scoggins CR, Loehle J, et al: Hepatic imaging characteristics predict overall survival in hepatocellular carcinoma. Ann Surg Oncol 14:2824-2830, 2007 (Pubitemid 47460659)
116. Ho CL, Chen S, Yeung DW, et al: Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 48:902-909, 2007 (Pubitemid 46909918)
117. Song I, Rhim H, Lim HK, et al: Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: Safety and technical efficacy in 143 patients. Eur Radiol 19:2630-2640, 2009
118. Zhu AX, Raymond E: Early development of sunitinib in hepatocellular carcinoma. Expert Rev Anticancer Ther 9:143-150, 2009
119. Faivre S, Raymond E, Boucher E, et al: Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, phase II study. Lancet Oncol 10:794-800, 2009
120. Finn RS, Kang Y, Park J, et al: Phase II, open label study of brivanib alaninate in patients (pts) with hepatocellular carcinoma (HCC) who failed prior antiangiogenic therapy. American Society of Clinical Oncology 2009 Gastrointestinal Cancers Symposium, San Francisco, CA, January 15-17, 2009 (abstr 200)
121. Thomas MB, Morris JS, Chadha R, et al: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27:843-850, 2009
122. Huynh H, Ngo VC, Koong HN, et al: AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol 52:79-87, 2010
123. Ito Y, Sasaki Y, Horimoto M, et al: Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27:951-958, 1998 (Pubitemid 28160479)
124. McKillop IH, Schmidt CM, Cahill PA, et al: Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma. Hepatology 26:1484-1491, 1997 (Pubitemid 27520013)
125. Yau T, Chan P, Epstein R, et al: Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 29:10-17, 2009
126. Zhou Q, He Q, Liang LJ: Expression of p27, cyclin E and cyclin A in hepatocellular carcinoma and its clinical significance. World J Gastroenterol 9:2450-2454, 2003 (Pubitemid 37461246)
127. Zhou H, Cheng B, Lin J: Expression of DNA repair enzyme hMTH1 mRNA and protein in hepatocellular carcinoma. J Huazhong Univ Sci Technolog Med Sci 25:389-392, 2005
128. Treiber G: mTOR inhibitors for hepatocellular cancer: A forward-moving target. Expert Rev Anticancer Ther 9:247-261, 2009
129. Sahin M, Allard BL, Yates M, et al: PPAR-gamma staining as a surrogate for PAX8/PPAR-gamma fusion oncogene expression in follicular neoplasms: Clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab 90:463-468, 2005 (Pubitemid 40116695)
130. Villanueva A, Chiang DY, Newell P, et al: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135:1972-1983, 2008
131. Fausto N: Growth factors in liver development, regeneration and carcinogenesis. Prog Growth Factor Res 3:219-234, 1991
132. Hisaka T, Yano H, Haramaki M, et al: Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: Relationship to cell proliferation. Int J Oncol 14:453-460, 1999
133. Zhu AX: Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112:250-259, 2008
134. Thomas MB, Chadha R, Glover K, et al: Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059-1067, 2007 (Pubitemid 47312872)
135. Philip PA, Mahoney MR, Allmer C, et al: Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657-6663, 2005 (Pubitemid 46190260)
136. Kanda M, Nomoto S, Nishikawa Y, et al: Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol 98:190-196, 2008
137. Shim JH, Park JW, Kim JH, et al: Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 99:2037-2044, 2008
138. Hu J, Xu Y, Shen ZZ, et al: High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J Cancer Res Clin Oncol 135:1359-1367, 2009
139. Finn RS, Zhu AX: Targeting angiogenesis in hepatocellular carcinoma: Focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 9:503-509, 2009
140. Azad NS, Posadas EM, Kwitkowski VE, et al: Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709-3714, 2008
141. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300, 2006 (Pubitemid 46630787)
142. Siegel AB, Cohen EI, Ocean A, et al: Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26:2992-2998, 2008
143. Huynh H, Chow PK, Palanisamy N, et al: Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol 49:52-60, 2008
144. Ma WW, Hidalgo M: Exploiting novel molecular targets in gastrointestinal cancers. World J Gastroenterol 13:5845-5856, 2007 (Pubitemid 350148501)
145. Höpfner M, Schuppan D, Scherübl H: Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 14:1-14, 2008
146. Marelli L, Stigliano R, Triantos C, et al: Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6-25, 2007 (Pubitemid 44900485)
147. Schoenleber SJ, Kurtz DM, Talwalkar JA, et al: Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: Systematic review and meta-analysis. Br J Cancer 100:1385-1392, 2009
148. Pleguezuelo M, Marelli L, Misseri M, et al: TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther 8:1623-1641, 2008